Also, according to the partnership agreement, Shenzhen Hepalink is responsible for all developmental costs for the licensed territories. This includes the cost of additional clinical trials in the licensed territories, regulatory applications, etc.

Perhaps they can do what they deem necessary to continue powering the BOM trial as they see fit (i.e.) a Bolt-on trial whatever that may be. I can't see them just standing still when they invested so much in the Apabetalone licence.

IMO...Koo